Journal
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 17, Issue 1, Pages 249-251Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-07-0722
Keywords
-
Funding
- NCI NIH HHS [P50 CA 090381, T32 CA 009001] Funding Source: Medline
- NIA NIH HHS [R01 AG 21404] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [T32CA009001, P50CA090381] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG021404] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Tumor molecular markers hold promise to distinguish potentially lethal from indolent prostate cancer and to guide treatment choices. A previous study identified a nine-gene molecular signature in tumors associated with prostate-specific antigen relapse after prostatectomy. We examined this molecular model in relation to prostate cancer death among 172 men with initially localized disease. We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available